AstraZeneca's FluMist Quadrivalent to hit U.S. market

The FDA has approved AstraZeneca's ($AZN) nasal FluMist Quadrivalent flu vaccine for use in people ages 2 to 49. Made at AstraZeneca's MedImmune unit, FluMist Quadrivalent contains two strains of influenza A and two strains of influenza B, and is the first to contain four strains of the influenza virus. Story